These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38629397)

  • 1. Tabletized Nanomedicine: From the Current Scenario to Developing Future Medicine.
    Tiwari R; Kolli M; Chauhan S; Yallapu MM
    ACS Nano; 2024 May; 18(18):11503-11524. PubMed ID: 38629397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-trimethyl chitosan chloride as absorption enhancer in oral peptide drug delivery. Development and characterization of minitablet and granule formulations.
    van der Merwe SM; Verhoef JC; Kotzé AF; Junginger HE
    Eur J Pharm Biopharm; 2004 Jan; 57(1):85-91. PubMed ID: 14729083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoformulations in Pharmaceutical and Biomedical Applications: Green Perspectives.
    Petrovic S; Bita B; Barbinta-Patrascu ME
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D Printing Technology as a Promising Tool to Design Nanomedicine-Based Solid Dosage Forms: Contemporary Research and Future Scope.
    Ahmad J; Garg A; Mustafa G; Mohammed AA; Ahmad MZ
    Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanotheranostics - application and further development of nanomedicine strategies for advanced theranostics.
    Muthu MS; Leong DT; Mei L; Feng SS
    Theranostics; 2014; 4(6):660-77. PubMed ID: 24723986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Nanomedicines and Nano-Similars: Recent Advances in Regulatory Landscape.
    Paliwal R; Kumar P; Chaurasiya A; Kenwat R; Katke S; Paliwal SR
    Curr Pharm Des; 2022; 28(2):165-177. PubMed ID: 34781869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicine and drug delivery systems in cancer and regenerative medicine.
    Garbayo E; Pascual-Gil S; Rodríguez-Nogales C; Saludas L; Estella-Hermoso de Mendoza A; Blanco-Prieto MJ
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Sep; 12(5):e1637. PubMed ID: 32351045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The drug delivery field at the inflection point: Time to fight its way out of the egg.
    Park K
    J Control Release; 2017 Dec; 267():2-14. PubMed ID: 28754609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mini-tablets: a contemporary system for oral drug delivery in targeted patient groups.
    Aleksovski A; Dreu R; Gašperlin M; Planinšek O
    Expert Opin Drug Deliv; 2015 Jan; 12(1):65-84. PubMed ID: 25200881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advance cardiac nanomedicine by targeting the pathophysiological characteristics of heart failure.
    Lin C; Gao H; Ouyang L
    J Control Release; 2021 Sep; 337():494-504. PubMed ID: 34358590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Theranostic applications of peptide-based nanoformulations for growth factor defective cancers.
    Ghosh A; Maske P; Patel V; Dubey J; Aniket K; Srivastava R
    Int J Biol Macromol; 2024 Mar; 260(Pt 2):129151. PubMed ID: 38181914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations.
    Ali Khan A; Mudassir J; Mohtar N; Darwis Y
    Int J Nanomedicine; 2013; 8():2733-44. PubMed ID: 23926431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted nanotheranostics for personalized cancer therapy.
    Diou O; Tsapis N; Fattal E
    Expert Opin Drug Deliv; 2012 Dec; 9(12):1475-87. PubMed ID: 23092183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in Nanomedicine Design: Multidisciplinary Strategies for Unmet Medical Needs.
    Ahmed T; Liu FF; Lu B; Lip H; Park E; Alradwan I; Liu JF; He C; Zetrini A; Zhang T; Ghavaminejad A; Rauth AM; Henderson JT; Wu XY
    Mol Pharm; 2022 Jun; 19(6):1722-1765. PubMed ID: 35587783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral nanomedicine approaches for the treatment of psychiatric illnesses.
    Dening TJ; Rao S; Thomas N; Prestidge CA
    J Control Release; 2016 Feb; 223():137-156. PubMed ID: 26739547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addressing the challenges to increase the efficiency of translating nanomedicine formulations to patients.
    Bhattacharjee S; Brayden DJ
    Expert Opin Drug Discov; 2021 Mar; 16(3):235-254. PubMed ID: 33108229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivering the power of nanomedicine to patients today.
    Germain M; Caputo F; Metcalfe S; Tosi G; Spring K; Åslund AKO; Pottier A; Schiffelers R; Ceccaldi A; Schmid R
    J Control Release; 2020 Oct; 326():164-171. PubMed ID: 32681950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanomedicine for Drug Delivery throughout the Alimentary Canal.
    Cote B; Rao D; Alani AWG
    Mol Pharm; 2022 Aug; 19(8):2690-2711. PubMed ID: 33605146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery.
    Moss DM; Curley P; Kinvig H; Hoskins C; Owen A
    Expert Rev Gastroenterol Hepatol; 2018 Mar; 12(3):223-236. PubMed ID: 29088978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microfluidic-Based Platform for the Evaluation of Nanomaterial-Mediated Drug Delivery: From High-Throughput Screening to Dynamic Monitoring.
    Yang Y; Liu S; Geng J
    Curr Pharm Des; 2019; 25(27):2953-2968. PubMed ID: 31362686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.